GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3 trial, painting ...
GE HealthCare is said to be on the cusp of buying out radiopharmaceutical developer Sofie Biosciences, according to a report by the Financial Times. | GE HealthCare is said to be on the cusp of buying ...
The announcement from Merck & Co. and Moderna last month that their mRNA cancer vaccine had successfully lengthened patient ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor zanzalintinib in combination with Roche’s ...
The 5-star Raffles Hotel in Boston was a fitting location for the launch of Singapore’s fifth international hub in the U.S., ...
MelliCell CEO Ben Pope, Ph.D., echoed the need for increased access to funds. The Greater Boston-based biotech company has a ...
A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...
The FDA has put enrollment in trials of Biohaven’s epilepsy drug candidate BHV-7000 on hold in response to findings from ...
Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...
ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing ...
Frazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results